Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO SIMPESSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 28 versus LO SIMPESSE.
DEMULEN 1/35-28 vs LO SIMPESSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial receptivity.
Bile acid sequestrant; binds bile acids in the intestine, forming an insoluble complex that is excreted in feces, thereby reducing enterohepatic circulation of bile acids and promoting conversion of cholesterol to bile acids in the liver, leading to decreased serum LDL cholesterol.
One tablet (contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol) orally once daily at the same time each day for 21 days, followed by 7 days of placebo or no tablets.
100 mg orally once daily, with or without food.
None Documented
None Documented
Ethinyl estradiol: 17.4 ± 5.6 h (terminal); norethindrone: 10.9 ± 1.6 h (terminal); clinically, steady-state achieved within 5-7 days.
Terminal elimination half-life is 12-16 hours in adults with normal renal function; may extend to >40 hours in severe renal impairment (CrCl <30 mL/min).
Renal 50% (metabolites), fecal 50% (biliary elimination of conjugates).
Primarily renal, with 70-80% of the dose excreted unchanged in urine; 10-20% via feces through biliary elimination.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive